TY - JOUR
T1 - Large scale investigation of GPCR molecular dynamics data uncovers allosteric sites and lateral gateways
AU - Aranda-García, David
AU - Stepniewski, Tomasz Maciej
AU - Torrens-Fontanals, Mariona
AU - García-Recio, Adrian
AU - Lopez-Balastegui, Marta
AU - Medel-Lacruz, Brian
AU - Morales-Pastor, Adrián
AU - Peralta-García, Alejandro
AU - Dieguez-Eceolaza, Miguel
AU - Sotillo-Nuñez, David
AU - Ding, Tianyi
AU - Drabek, Matthäus
AU - Jacquemard, Célien
AU - Jakowiecki, Jakub
AU - Jespers, Willem
AU - Jiménez-Rosés, Mireia
AU - Jun-Yu-Lim, Víctor
AU - Nicoli, Alessandro
AU - Orzel, Urszula
AU - Shahraki, Aida
AU - Tiemann, Johanna K.S.
AU - Ledesma-Martin, Vicente
AU - Nerín-Fonz, Francho
AU - Suárez-Dou, Sergio
AU - Canal, Oriol
AU - Pándy-Szekeres, Gáspár
AU - Mao, Jiafei
AU - Gloriam, David E.
AU - Kellenberger, Esther
AU - Latek, Dorota
AU - Guixà-González, Ramon
AU - Gutiérrez-de-Terán, Hugo
AU - Tikhonova, Irina G.
AU - Hildebrand, Peter W.
AU - Filizola, Marta
AU - Babu, M. Madan
AU - Di Pizio, Antonella
AU - Filipek, Slawomir
AU - Kolb, Peter
AU - Cordomi, Arnau
AU - Giorgino, Toni
AU - Marti-Solano, Maria
AU - Selent, Jana
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/2/27
Y1 - 2025/2/27
N2 - G protein-coupled receptors (GPCRs) constitute a functionally diverse protein family and are targets for a broad spectrum of pharmaceuticals. Technological progress in X-ray crystallography and cryogenic electron microscopy has enabled extensive, high-resolution structural characterisation of GPCRs in different conformational states. However, as highly dynamic events underlie GPCR signalling, a complete understanding of GPCR functionality requires insights into their conformational dynamics. Here, we present a large dataset of molecular dynamics simulations covering 60% of currently available GPCR structures. Our analysis reveals extensive local “breathing” motions of the receptor on a nano- to microsecond timescale and provides access to numerous previously unexplored receptor conformational states. Furthermore, we reveal that receptor flexibility impacts the shape of allosteric drug binding sites, which frequently adopt partially or completely closed states in the absence of a molecular modulator. We demonstrate that exploring membrane lipid dynamics and their interaction with GPCRs is an efficient approach to expose such hidden allosteric sites and even lateral ligand entrance gateways. The obtained insights and generated dataset on conformations, allosteric sites and lateral entrance gates in GPCRs allows us to better understand the functionality of these receptors and opens new therapeutic avenues for drug-targeting strategies.
AB - G protein-coupled receptors (GPCRs) constitute a functionally diverse protein family and are targets for a broad spectrum of pharmaceuticals. Technological progress in X-ray crystallography and cryogenic electron microscopy has enabled extensive, high-resolution structural characterisation of GPCRs in different conformational states. However, as highly dynamic events underlie GPCR signalling, a complete understanding of GPCR functionality requires insights into their conformational dynamics. Here, we present a large dataset of molecular dynamics simulations covering 60% of currently available GPCR structures. Our analysis reveals extensive local “breathing” motions of the receptor on a nano- to microsecond timescale and provides access to numerous previously unexplored receptor conformational states. Furthermore, we reveal that receptor flexibility impacts the shape of allosteric drug binding sites, which frequently adopt partially or completely closed states in the absence of a molecular modulator. We demonstrate that exploring membrane lipid dynamics and their interaction with GPCRs is an efficient approach to expose such hidden allosteric sites and even lateral ligand entrance gateways. The obtained insights and generated dataset on conformations, allosteric sites and lateral entrance gates in GPCRs allows us to better understand the functionality of these receptors and opens new therapeutic avenues for drug-targeting strategies.
UR - https://www.scopus.com/pages/publications/85219637527
U2 - 10.1038/s41467-025-57034-y
DO - 10.1038/s41467-025-57034-y
M3 - Article
C2 - 40016203
AN - SCOPUS:85219637527
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 2020
ER -